Abstract Body

Drug-sparing strategies have been explored lately, aiming to improve tolerability and adherence, reduce toxicity, and costs.  Two studies have shown non inferiority of dual therapy in ARV –naïve HIV-1 infected individuals (NEAT and GARDEL).  The PADDLE study showed that a dual therapy regimen based on dolutegravir plus lamivudine (DTG/3TC) induced a rapid viral decay in treatment naïve patients with screening pVL <100K (EACS 2015). Our objective is  to compare differences between plasma viral load (pVL) change at each time point  with a dual therapy, DTG/3TC, to triple therapy regimens used in the SPRING-1 (DTG 50 mg +2NRTIs) and SINGLE study (DTG plus abacavir/lamivudine), in patients with baseline (BL) pVL < 100,000 copies/mL.

In PADDLE (n=20), pVL was tested at BL, days 2, 4, 7, 10, weeks 2, 4, 8, 12, 24 and thereafter. In SINGLE (n=280) it was measured at BL, wk 2, 4, 8, 12, 16, 24 and thereafter. In SPRING-1 (n=39) pVL was measured at BL, wk 1, 2, 4, 8, 12, 16, 20, 24 and thereafter. Change in pVL vs. baseline was calculated only for time points with data for the three studies (Weeks 2, 4, 8, 12 and 24). Effects of time and treatment, was analyzed by two-way ANOVA, followed by Tukey-HSD post-hoc test.

BL pVL (Mean+SD) was 4.43 (0.50), 4.30 (0.45) and 4.31 (0.52) for PADDLE, SINGLE and SPRING-1 respectively.  Rapid decline in viral load was observed in the three regimens. Two-way ANOVA revealed significant effects for treatment (F2,1605=30.3 p<0.001) and time (F4,1605=22.8 p<0.001), without significant interactions. Average effects of treatment in PADDLE, SPRING-1 and SINGLE were -2.75±0.45 (Mean ±SD), -2.53±0.49 and -2.61±0.48 log10 respectively. Significant differences were observed between PADDLE and SPRING-1 or SINGLE studies (p<0.01 and p<0.05).

The figure shows the viral load change at each time point in the studies (Mean ± Standard error of the mean)

Viral load change was of similar magnitude after a dual therapy regimen DTG/3TC compared to 2 DTG-based triple therapy regimens. These results, albeit encouraging, should be interpreted with caution, as the analysis is based on a cross-study comparison of mean values and PADDLE is a small pilot study. Full powered, randomized studies are in progress to evaluate DTG/3TC as a valid option for first line therapy.